FDA approves Roche breast cancer drug giredestrant
The US Food and Drug Administration has approved Roche’s breast cancer medicine giredestrant, clearing the way for a launch the company has said could make the drug its top-selling product ever. STAT reports that this was among the most important regulatory decisions Roche had been waiting on, and that it gives the Swiss group another foothold in a disease area where it already has a long record through Genentech’s Herceptin.
That history still matters commercially and clinically, but the same reporting notes that Roche has slipped behind rivals in oncology in recent years. Giredestrant is therefore being watched as a chance to rebuild that franchise rather than as a routine label expansion.
Analysts, according to STAT, broadly expect the medicine to become a multibillion-dollar blockbuster if Roche later wins approval in other forms of breast cancer. The first US clearance does not by itself deliver that scale; it is the opening step that lets Roche start selling in the approved setting while it pursues broader use. For patients and clinicians, the immediate news is a new FDA-approved option from a company that helped define modern breast cancer treatment with Herceptin, now trying to catch up in a more crowded field.
Continue in the app — vote & join in ➔